Skip to content
Decision-ready map
• System: device → tissue optics → heat → biology → adverse events
• Key variable: melanin-dependent absorption affects thermal rise
• Engineering levers: dosimetry control, sensing, modeling, UI guardrails
• Validation: stratified safety endpoints + reproducible parameter reporting
(1) What it is
Thermal injury disparity is a systems engineering problem. A light-therapy system converts electrical power to optical output (spectrum, beam profile, pulse structure). Tissue optics determine absorption and heat generation. Because melanin absorbs strongly in visible and parts of NIR, higher epidermal melanin can increase local energy deposition and temperature rise for the same nominal settings, shrinking safety margins.
(2) Who it helps
This brief helps engineers working on device hardware, thermal management, sensors, firmware, UI/UX, and ML-driven protocol selection for PBM/LED/laser/IPL systems who need to translate clinical equity signals into engineering requirements.
(3) What evidence exists
A clinical cohort reported increased photosensitivity and substantially higher odds of clinically visible thermal injury for darker skin under a PBM protocol (https://doi.org/10.1111/phpp.70042). Reviews describe higher complication susceptibility in skin of color when parameters are not adapted (https://doi.org/10.4103/ijdvl.IJDVL_88_17) and catalog IPL complications including burns and pigment changes (https://doi.org/10.1002/der2.57). PBM dosimetry literature emphasizes that incomplete parameter reporting undermines comparability and safety engineering (https://doi.org/10.21037/atm.2016.05.34). FDA PBM guidance articulates expectations for testing and labeling for medical claims (FDA webpage).
(4) Translation barriers
Engineering teams often lack a consistent ‘dose truth.’ Reporting only nominal power or total energy omits beam profile, spot size, distance, duty cycle, and cooling—variables that determine irradiance at the skin and thermal rise. Skin tone is often treated as a demographic field rather than an optical boundary condition. Field variability (contact pressure, hydration, ambient temperature) can dominate thermal behavior, so bench tests may not predict adverse events without robust modeling and sensing.
(5) Equity/safety checks
Treat skin pigmentation as an engineering input. Add conservative safety margins and quality indicators: contact sensors, distance control, real-time temperature sensing, reflectance-based coupling estimation, and auto shut-off thresholds. Provide UI guardrails: bounded parameter ranges, protocol ramping, prompts for cooling/site change. If using ML, evaluate subgroup safety and avoid shortcut learning on skin-tone proxies.
(6) Decision questions
• What thermal model (optical absorption → heat diffusion) predicts worst-case temperature rise under high melanin / low perfusion?
• Which variables dominate risk: irradiance peaks, duty cycle, coupling, or cooling failure?
• Are safety endpoints evaluated as tail risk, not only average temperature rise?
• Is validation stratified by skin tone/phototype and real use conditions?
(7) Practical next steps
1) Specify dose precisely: wavelength, beam profile, spot size, irradiance at skin, pulse/duty cycle, exposure time, coupling and cooling.
2) Build a thermal safety layer: sensing + shutdown + logs.
3) Validate with stratified endpoints (burns, pain, pigment changes) and preregistered analyses.
4) Produce an ‘equity dossier’ for procurement/regulatory: stratified safety outcomes, tested conditions, and limitations.
(8) References
https://doi.org/10.1111/phpp.70042
https://doi.org/10.4103/ijdvl.IJDVL_88_17
https://doi.org/10.1002/der2.57
https://doi.org/10.21037/atm.2016.05.34
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions